Navigation Links
Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress

REDWOOD CITY, Calif., Jan. 24 /PRNewswire-FirstCall/ -- Cardica, Inc. (Nasdaq: CRDC) today reported financial results and corporate progress for its fiscal 2008 second quarter and six months ended December 31, 2007.

"We continue to make excellent commercial progress, with over 1,000 C-Port systems shipped in the past quarter for the first time, an expanding product line designed to enable minimally-invasive cardiac surgery and substantial advancement for our development-stage products," said Bernard A. Hausen, M.D., Ph.D., president and chief executive officer of Cardica, Inc. "Moving forward, we will build on our momentum with a significant presence at the Annual Meeting of the Society for Thoracic Surgeons (STS) next week where we will feature our reloadable, cartridge-based C-Port(R) xA X-CHANGE(TM) system, host a joint robotic seminar with Intuitive Surgical, participate in a physician education event featuring our anastomosis products and train surgeons on the use of our devices at STS University."

Recent Highlights and Accomplishments

Commercial Progress

-- Trained a total of 232 surgeons on C-Port(R) Distal Anastomosis Systems

since product introduction;

-- Increased cumulative worldwide shipments of C-Port systems to over

3,600 units, with more than 1,000 units sold in the fiscal 2008 second


-- Increased cumulative worldwide shipments of PAS-Port(R) Proximal

Anastomosis Systems to over 7,300 units, with more than 560 units sold

in the fiscal 2008 second quarter, of which the vast majority of units

were deployed in Japan;

-- Reported data at the 2007 American Heart Association Scientific

Sessions demonstrating that C-Port xA(R) and C-Port(R) Flex-A(R) Distal

Anastomosis Systems produce excellent patency in off-pump cardiac

bypass surgery;

-- Hosted a premier live webcast demonstrating the use of the C-Port xA

and the C-Port Flex-A systems during an off-pump coronary artery bypass

graft (CABG) procedure and a taped robotic closed-chest bypass surgery,

respectively; and

-- Launched C-Port xA X-CHANGE system, a cartridge-based system, and will

feature it at the Annual Meeting of the Society of Thoracic Surgeons

which is taking place Jan. 25-30 in Fort Lauderdale, Fla.


-- Raised $15.4 million in net proceeds through the sale of 1,981,170

shares of Cardica's common stock; and

-- Received $2 million from Cook Medical for multiple milestones under the

Cook Vascular Closure Device and patent foramen ovale (PFO) license,

development and commercialization agreements.

Fiscal 2008 Second Quarter and Six Months Ended December 31, 2007 Financial Results

Total revenue was approximately $1.7 million for the fiscal 2008 second quarter compared to approximately $0.9 million for the fiscal 2007 second quarter. Total product revenue was approximately $1.3 million for the fiscal 2008 second quarter compared to approximately $0.4 million for the same period in fiscal 2007. Cost of product revenue was approximately $1.2 million for the fiscal 2008 second quarter compared to approximately $0.9 million for the fiscal 2007 second quarter.

Research and development expenses were approximately $1.7 million for both the fiscal 2008 and 2007 second quarters. Selling, general and administrative expenses for the fiscal 2008 second quarter were approximately $3.2 million compared to approximately $2.2 million for the same period in fiscal 2007.

The net loss for the fiscal 2008 second quarter was approximately $4.2 million, or $0.29 per share, compared to a net loss of approximately $2.5 million, or $0.23 per share, for the fiscal 2007 second quarter.

Total net revenue for the six months ended December 31, 2007 was approximately $3.0 million compared to approximately $1.4 million for the same period of fiscal 2007. Total operating costs and expenses for the six months ended December 31, 2007 were approximately $11.4 million compared to approximately $9.0 million for the same period of fiscal 2007. The net loss for the first six months of fiscal 2008 was approximately $7.8 million, or $0.56 per share, compared to a net loss of approximately $6.1 million, or $0.60 per share, for the same period of fiscal 2007.

Cash and investments at December 31, 2007 were $30.9 million, compared to $18.9 million at September 30, 2007. The Cook $2.0 million payment was deposited in January 2008 and is not included in the year-end cash and investments balance. As of December 31, 2007, there were approximately 15.7 million shares of common stock outstanding.

Financial Guidance for Fiscal 2008:

For the full fiscal year 2008, we continue to expect total revenue of $6 million to $8 million, of which we expect product revenue of $4 million to $5 million. In addition, we continue to expect development revenue of $2 million to $3 million. We continue to anticipate that fiscal 2008 research and development, and selling, general and administrative expenses will total $20 million to $21 million, including non-cash stock-based compensation expense of approximately $2 million. We continue to expect that the net loss for fiscal 2008 will be between $16 million and $18 million.

Conference Call Details

We will hold a live conference call today, January 24, 2008 at 4:30 p.m. Eastern Time to discuss our fiscal second quarter financial results and provide an update on the business. To access the live conference call via phone, please dial 800-659-1966 in the United States and Canada or 617-614-2711 internationally. The conference ID is 37076673. Please dial in approximately ten minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through January 31, 2008 and may be accessed by dialing 888-286-8010 from the United States and Canada or 617-801-6888 internationally. The replay passcode is 33900859.

To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of Cardica's website at Please connect to the website at least 15 minutes prior to the call to allow for any necessary software downloads.

About Cardica, Inc.

Cardica is a leading provider of automated anastomosis systems for coronary artery bypass graft (CABG) surgery. By replacing hand-sewn sutures with easy-to-use automated systems, Cardica's products provide cardiovascular surgeons with rapid, reliable and consistently reproducible anastomoses, or connections of blood vessels, often considered the most critical aspect of the CABG procedure. Cardica's C-Port(R) Distal Anastomosis Systems are marketed in Europe and the United States. The PAS-Port(R) Proximal Anastomosis System is marketed in Europe and Japan and is being evaluated in a pivotal trial in the United States and Europe. Cardica also is developing additional devices with Cook Incorporated to facilitate vascular closure and other surgical procedures.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements under the heading "Financial Guidance for Fiscal 2008." The words "anticipate," "expect," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Cardica's current expectations. Forward-looking statements involve risks and uncertainties. Cardica's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks associated with Cardica's dependence upon the success of its current products, market acceptance of Cardica's C-Port(R) Distal Anastomosis Systems, manufacturing of the C-Port(R) Distal Anastomosis Systems and PAS-Port(R) Proximal Anastomosis System and our suppliers, Cardica's sales, marketing and distribution strategy and capabilities, success of pre-clinical studies of and regulatory activities related to the Cook Vascular Closure Device and specialized PFO closure device, the timing of completion and success of the multi-national clinical trial evaluating Cardica's PAS-Port Proximal Anastomosis System and Cardica's need for additional funding. These and other risk factors are discussed under "Risk Factors" in Cardica's Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2007. Cardica expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. You are encouraged to read the Company's reports filed with the U.S. Securities and Exchange Commission, available at

~ financial statements to follow ~

Cardica, Inc.

Statements of Operations

(amounts in thousands except per share amounts)

Three months ended Six months ended

December 31, December 31,

2007 2006 2007 2006

(unaudited) (unaudited)


Product revenue, net $1,283 $416 $2,309 $874

Development revenue 395 500 702 500

Royalty revenue from

related-party 16 12 32 25

Total revenue 1,694 928 3,043 1,399

Operating costs and


Cost of product

revenue 1,199 884 2,212 1,563

Research and

development 1,746 1,661 3,434 3,149

Selling, general and

administrative 3,176 2,203 5,729 4,273

Total operating costs

and expenses 6,121 4,748 11,375 8,985

Loss from operations (4,427) (3,820) (8,332) (7,586)

Interest income 283 298 553 687

Interest expense (25) (132) (50) (396)

Other income 2 - 3 -

Gain on early retirement

of notes payable to

related-party - 1,183 - 1,183

Net loss $(4,167) $(2,471) $(7,826) $(6,112)

Basic and diluted net

loss per share $(0.29) $(0.23) $(0.56) $(0.60)

Shares used in computing

basic and diluted net

loss per share 14,471 10,642 14,037 10,210

Condensed Balance

Sheets (amounts

in thousands) December 31, June 30,

2007 2007

Assets (unaudited) (Note 1)

Cash and investments $30,903 $23,434

Other assets 4,513 3,890

Total assets $35,416 $27,324

Liabilities and

stockholders' equity

Total current

liabilities $3,008 $3,315

Total long-term

liabilities 2,000 2,020

Stockholders' equity 30,408 21,989

Total liabilities

and stockholders'

equity $35,416 $27,324

(1) Derived from audited financial statements

SOURCE Cardica, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cardica and Intuitive Surgical to Host Educational Symposium on Advanced Techniques and Technologies in Robotic Coronary Revascularization and Mitral Valve Repair
2. Cardica and Cook Sign Agreement to Expand Cook Vascular Closure Device Product Family
3. Cardica Receives European CE Mark for C-Port Flex A System for Use in Coronary Artery Bypass Surgery
4. Cardicas C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries
5. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
6. Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO & Investor Conference
7. Accuray Announces New Treatment Planning Service Offering
8. QED International Associates Announces Changes to the HealthShares(TM) Composite, HealthShares(TM) Cancer and HealthShares(TM) Neuroscience Indexes
9. Sharps Compliance Corp. Announces Purchase of Medical Waste Disposal Facility and Addition of Autoclave Technology
10. ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use
11. Vapotherm(R) Announces Validation of U.S. Patent
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... They call ... complex biological network, a depiction of a system of linkages and connections so ... PhD, associate professor of computer science at Worcester Polytechnic Institute (WPI) and director ...
(Date:10/12/2017)... ... 12, 2017 , ... AMRI, a global contract research, development ... patient outcomes and quality of life, will now be offering its impurity solutions ... new regulatory requirements for all new drug products, including the finalization of ICH ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ComplianceOnline’s Medical ... place on 7th and 8th June 2018 in San Francisco, CA. The Summit brings ... well as several distinguished CEOs, board directors and government officials from around the world ...
(Date:10/11/2017)... ... 2017 , ... A new study published in Fertility and ... in vitro fertilization (IVF) transfer cycles. The multi-center matched cohort study ... comparing the results from the fresh and frozen transfer cohorts, the authors of ...
Breaking Biology Technology:
(Date:8/15/2017)... --  ivWatch LLC , a medical device company focused on improving ... of its ISO 13485 Certification, the global standard for medical device ... (ISO®). ... Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as it ...
(Date:6/23/2017)... ITHACA, N.Y. , June 23, 2017  IBM ... in dairy research, today announced a new collaboration using ... the chances that the global milk supply is impacted ... project, Cornell University has become the newest academic institution ... Chain, a food safety initiative that includes IBM Research, ...
(Date:5/16/2017)... N.J. , May 16, 2017  Veratad Technologies, ... provider of online age and identity verification solutions, announced ... K(NO)W Identity Conference 2017, May 15 thru May 17, ... Regan Building and International Trade Center. ... the globe and in today,s quickly evolving digital world, ...
Breaking Biology News(10 mins):